Boulder Hill Capital Management’s Ginkgo Bioworks DNA Stock Holding History
Bought
Maintained
Sold
Other funds holding DNA
AIM
ACG
NAMA
Boulder Hill Capital Management's DNA Position: Q4 2023 in Review
Boulder Hill Capital Management sold out of Ginkgo Bioworks (DNA) in Q4 2023, closing a stake of 36,575 shares — an estimated $2.65M sold.
Boulder Hill Capital Management first reported a position in DNA in Q3 2023 and held it in 1 quarter. The position peaked at $2.65M in Q3 2023. 342 funds tracked by Wall St. Rank hold DNA as of Q4 2023.
- Boulder Hill Capital Management reported no remaining Ginkgo Bioworks position as of Q4 2023 after selling out during the quarter.
- Boulder Hill Capital Management sold 36,575 Ginkgo Bioworks shares in Q4 2023, an estimated $2.65M.
- Boulder Hill Capital Management first reported a position in Ginkgo Bioworks in Q3 2023 and held it in 1 quarter.
- Boulder Hill Capital Management's Ginkgo Bioworks position peaked at $2.65M in Q3 2023.
- 342 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q4 2023.
Based on Boulder Hill Capital Management's 13F filing for Q4 2023, filed 12 Feb 2024.